Incyte Corp [INCY]
$79.88 1.51 (1.86%)
Market Cap 17.18 Billion
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.
EPS 0.48 P/E Ratio 145.02
Previous Earnings Tue, Apr 30, 2019
Latest Earnings Tue, Jul 30, 2019 (In 13 days)
Pay Date --
|Symbol||Price||Day %||YTD %|
This list of trending stocks may change throughout the trading day.